{"title":"Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective.","authors":"Gunawan Indrayanto","doi":"10.1016/bs.podrm.2023.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Herbal drugs (HD) or traditional drugs have been used worldwide for centuries, especially in the developing countries. Global market of HD reaches billion of USD annually and increases every year. For ensuring the safety and efficacy of HD, the Drug Agency/Authority issues regulations for the registration & application of new HD, their manufacturing processes, controlling and monitoring in the market. The efficacy and safety of HD depend on their whole chemical contents. Quality assessment of HD should be performed using standardization methods according to the current Pharmacopoeias or Materia Medica. Unfortunately, the official methods of the compendia cannot be applied for evaluation of mixed herbs and their preparations.; HD's producers should develop, validate, and standardize the method for the quality assessment of their own specific products. Therefore, assuring the safety and efficacy of HD remains a challenging task due to the complex nature of HD, that typically consist of many constituents of herbs/extracts whose quality may vary among different sources of materials. This present review will describe, compare, and discuss the regulations and standardization methods of HD from US, EU countries, Japan, Taiwan, Hong Kong and Indonesia. The official standardization methods of HD, their current criteria, limitations, challenge and future prospective will be described and discussed. Official methods for quality assessment of HD should be state of the art, fast, low-cost, accurate and precise, and could be used for evaluation of all kinds of HD.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"49 ","pages":"153-199"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2023.11.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Herbal drugs (HD) or traditional drugs have been used worldwide for centuries, especially in the developing countries. Global market of HD reaches billion of USD annually and increases every year. For ensuring the safety and efficacy of HD, the Drug Agency/Authority issues regulations for the registration & application of new HD, their manufacturing processes, controlling and monitoring in the market. The efficacy and safety of HD depend on their whole chemical contents. Quality assessment of HD should be performed using standardization methods according to the current Pharmacopoeias or Materia Medica. Unfortunately, the official methods of the compendia cannot be applied for evaluation of mixed herbs and their preparations.; HD's producers should develop, validate, and standardize the method for the quality assessment of their own specific products. Therefore, assuring the safety and efficacy of HD remains a challenging task due to the complex nature of HD, that typically consist of many constituents of herbs/extracts whose quality may vary among different sources of materials. This present review will describe, compare, and discuss the regulations and standardization methods of HD from US, EU countries, Japan, Taiwan, Hong Kong and Indonesia. The official standardization methods of HD, their current criteria, limitations, challenge and future prospective will be described and discussed. Official methods for quality assessment of HD should be state of the art, fast, low-cost, accurate and precise, and could be used for evaluation of all kinds of HD.
草药(HD)或传统药物已在全球使用了几个世纪,尤其是在发展中国家。全球草药市场每年达到数十亿美元,并且每年都在增长。为确保草药的安全性和有效性,药品管理局/主管部门对新草药的注册和应用、生产工艺、市场控制和监测发布了相关规定。人类免疫缺损病毒的疗效和安全性取决于其全部化学成分。应根据现行的《药典》或《本草纲目》,采用标准化方法对人类免疫缺损病毒进行质量评估。遗憾的是,药典中的官方方法不能用于评估混合药材及其制剂。因此,确保人类免疫缺损病毒的安全性和有效性仍然是一项具有挑战性的任务,因为人类免疫缺损病毒的性质复杂,通常由多种草药/提取物成分组成,不同来源的材料质量可能不同。本综述将介绍、比较和讨论美国、欧盟国家、日本、台湾、香港和印度尼西亚的 HD 法规和标准化方法。将对 HD 的官方标准化方法、其现行标准、局限性、挑战和未来前景进行描述和讨论。HD 质量评估的官方方法应是最先进的、快速的、低成本的、准确的和精确的,并可用于各种 HD 的评估。